TY - JOUR
T1 - Structure and molecular recognition mechanism of IMP-13 metallo-β-lactamase
AU - Softley, Charlotte A.
AU - Zak, Krzysztof M.
AU - Bostock, Mark J.
AU - Fino, Roberto
AU - Zhou, Richard Xu
AU - Kolonko, Marta
AU - Mejdi-Nitiu, Ramona
AU - Meyer, Hannelore
AU - Sattler, Michael
AU - Popowicz, Grzegorz M.
N1 - Publisher Copyright:
Copyright © 2020 American Society for Microbiology. All Rights Reserved.
PY - 2020/6
Y1 - 2020/6
N2 - Multidrug resistance among Gram-negative bacteria is a major global public health threat. Metallo-β-lactamases (MBLs) target the most widely used antibiotic class, the β-lactams, including the most recent generation of carbapenems. Interspecies spread renders these enzymes a serious clinical threat, and there are no clinically available inhibitors. We present the crystal structures of IMP-13, a structurally uncharacterized MBL from the Gram-negative bacterium Pseudomonas aeruginosa found in clinical outbreaks globally, and characterize the binding using solution nuclear magnetic resonance spectroscopy and molecular dynamics simulations. The crystal structures of apo IMP-13 and IMP-13 bound to four clinically relevant carbapenem antibiotics (doripenem, ertapenem, imipenem, and meropenem) are presented. Active-site plasticity and the active-site loop, where a tryptophan residue stabilizes the antibiotic core scaffold, are essential to the substrate-binding mechanism. The conserved carbapenem scaffold plays the most significant role in IMP-13 binding, explaining the broad substrate specificity. The observed plasticity and substrate-locking mechanism provide opportunities for rational drug design of novel metallo-β-lactamase inhibitors, essential in the fight against antibiotic resistance.
AB - Multidrug resistance among Gram-negative bacteria is a major global public health threat. Metallo-β-lactamases (MBLs) target the most widely used antibiotic class, the β-lactams, including the most recent generation of carbapenems. Interspecies spread renders these enzymes a serious clinical threat, and there are no clinically available inhibitors. We present the crystal structures of IMP-13, a structurally uncharacterized MBL from the Gram-negative bacterium Pseudomonas aeruginosa found in clinical outbreaks globally, and characterize the binding using solution nuclear magnetic resonance spectroscopy and molecular dynamics simulations. The crystal structures of apo IMP-13 and IMP-13 bound to four clinically relevant carbapenem antibiotics (doripenem, ertapenem, imipenem, and meropenem) are presented. Active-site plasticity and the active-site loop, where a tryptophan residue stabilizes the antibiotic core scaffold, are essential to the substrate-binding mechanism. The conserved carbapenem scaffold plays the most significant role in IMP-13 binding, explaining the broad substrate specificity. The observed plasticity and substrate-locking mechanism provide opportunities for rational drug design of novel metallo-β-lactamase inhibitors, essential in the fight against antibiotic resistance.
KW - Antibiotic resistance
KW - IMP-13
KW - Imipenemase
KW - Metallo-β-lactamase
KW - Metalloenzyme
KW - Molecular dynamics
KW - Nuclear magnetic resonance
KW - Protein dynamics
KW - Solution NMR
KW - X-ray crystallography
KW - β-lactam antibiotic
UR - http://www.scopus.com/inward/record.url?scp=85085265617&partnerID=8YFLogxK
U2 - 10.1128/AAC.00123-20
DO - 10.1128/AAC.00123-20
M3 - Article
C2 - 32205343
AN - SCOPUS:85085265617
SN - 0066-4804
VL - 64
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 6
M1 - e00123-20
ER -